Results 201 to 210 of about 280,456 (250)

Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease

Journal of Clinical Lipidology, 2019
Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD). In the United States, lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany uses LA therapy for patients with an Lp(a) > 60 mg/dL, normal low-density lipoprotein cholesterol (LDL-C) levels, and CVD.
Patrick M, Moriarty, Jessica V, Gray, Lauryn K, Gorby   +2 more
openaire   +3 more sources

Lipoprotein Apheresis

Endocrinology and Metabolism Clinics of North America, 2015
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients ...
Patrick M, Moriarty, Linda, Hemphill
  +8 more sources

Skin microcirculation significantly increases after lipoprotein apheresis

Therapeutic Apheresis and Dialysis, 2023
Dear Editor, Lipoprotein apheresis (LA) is the therapeutic “last chance saloon” for inherited dyslipidemias resistant/intolerant to lipid lowering drugs [1].
Francesco Sbrana, Beatrice Dal Pino, Tiziana Sampietro   +2 more
openaire   +3 more sources

Inclisiran and lipoprotein apheresis in statin intolerance heterozygous FH patients: A case series

Therapeutic apheresis and dialysis, 2023
Dear Editor, In Familial Hypercholesterolemia (FH), statins treatment is the first choice to lower LDL cholesterol and to reduce cardiovascular morbidity and mortality, however, up to 10% of patients treated with statins report intolerance [1 ...
B. Dal Pino, F. Bigazzi, F. Sbrana
semanticscholar   +1 more source

Current status of low‐density lipoprotein apheresis treatment for patients with peripheral artery disease and chronic kidney disease in Japanese clinical database

Therapeutic apheresis and dialysis, 2023
Patients with peripheral arterial disease (PAD) have a poorer prognosis than those without PAD. PAD complications worsen the prognosis of patients with chronic kidney disease (CKD), especially those on maintenance dialysis.
Yu Watanabe, Akihito Tanaka, K. Furuhashi, S. Maruyama   +3 more
semanticscholar   +1 more source

The German Lipoprotein Apheresis Registry—Summary of the ninth annual report

Therapeutic apheresis and dialysis, 2022
During 2012–2020, 89 German apheresis centers collected retrospective and prospective observational data of 2028 patients undergoing regular lipoprotein apheresis (LA) for the German Lipoprotein Apheresis Registry (GLAR). More than 47 500 LA sessions are
Volker J J Schettler, C. Peter, T. Zimmermann, U. Julius, E. Roeseler, G. Schlieper, F. Heigl, P. Grützmacher, I. Löhlein, R. Klingel, B. Hohenstein, W. Ramlow, A. Vogt   +12 more
semanticscholar   +1 more source

Angiographic and clinical impact of novel low‐density lipoprotein apheresis for no‐option chronic limb‐threatening ischemia

Therapeutic apheresis and dialysis, 2022
Dear Editor, Chronic limb-threatening ischemia (CLTI), the most advanced form of peripheral artery disease, has a poor prognosis. Despite the rapid development of therapeutic strategies, no-option CLTI, in which arterial revascularization fails or is ...
Shunsuke Kojima, T. Nakama, K. Obunai
semanticscholar   +1 more source

Lipoprotein(a) apheresis

Current Opinion in Lipidology, 2016
Purpose of review Currently, different methods for extracorporeal elimination of atherogenic apolipoprotein B100 containing lipoprotein particles are used in clinical practice. Most of them effectively remove both lipoprotein(a) [Lp(a)] and LDL.
Sergei N, Pokrovsky, Olga I, Afanasieva, Marat V, Ezhov   +2 more
openaire   +2 more sources

Low‐density lipoprotein apheresis for recurrent focal segmental glomerulosclerosis post renal transplant in pediatric patients

Journal of clinical apheresis, 2022
Low‐density lipoprotein (LDL) apheresis has been shown to improve remission in patients with steroid‐resistant nephrotic syndrome (SRNS). Here, we report a case study of two patients who failed apheresis treatment for SRNS and required transplant with ...
Mohammad F Al-Mousily, O. Nicoara, D. Selewski, S. Nadig, K. Twombley   +4 more
semanticscholar   +1 more source

Lipoprotein apheresis influences monocyte subpopulations

Atherosclerosis Supplements, 2017
Monocytes can be differentiated into subpopulations depending on their expression profile of CD14 and CD16. CD16-positive monocytes are associated with coronary artery disease. Up to now, no data exist about the effect of lipoprotein apheresis (LA) on the distribution of monocyte subpopulations.80 patients who underwent LA at the University Hospital ...
Jellinghaus, S, Reich, C, Schatz, U, Tselmin, S, Ibrahim, K, Pfluecke, C, Schauer, A, Bornstein, S R, Hohenstein, B, Strasser, R H, Julius, U, Poitz, D M   +11 more
openaire   +3 more sources